Market Analysis and Insights: Global Pulmonary Arterial Hypertension (PAH) Market
The global Pulmonary Arterial Hypertension (PAH) market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Prostacyclin and Prostacyclin Analogs accounting for % of the Pulmonary Arterial Hypertension (PAH) global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hospital segment is altered to an % CAGR throughout this forecast period.
China Pulmonary Arterial Hypertension (PAH) market size is valued at US$ million in 2021, while the North America and Europe Pulmonary Arterial Hypertension (PAH) are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Pulmonary Arterial Hypertension (PAH) landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Pulmonary Arterial Hypertension (PAH) market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Pulmonary Arterial Hypertension (PAH) market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Pulmonary Arterial Hypertension (PAH) market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Pulmonary Arterial Hypertension (PAH) market.
Global Pulmonary Arterial Hypertension (PAH) Scope and Market Size
Pulmonary Arterial Hypertension (PAH) market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Pulmonary Arterial Hypertension (PAH) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
- Prostacyclin and Prostacyclin Analogs
- SGC Stimulators
- ERA
- PDE-5
Segment by Application
By Company
- Actelion
- Gilead Sciences
- United Therapeutics
- GlaxoSmithKline
- Pfizer
- Bayer
- Arena
By Region
- North America
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Nordic Countries
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
TABLE OF CONTENTS
1 Report Business Overview
- 1.1 Study Scope
- 1.2 Market Analysis by Type
- 1.2.1 Global Pulmonary Arterial Hypertension (PAH) Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
- 1.2.2 Prostacyclin and Prostacyclin Analogs
- 1.2.3 SGC Stimulators
- 1.2.4 ERA
- 1.2.5 PDE-5
- 1.3 Market by Application
- 1.3.1 Global Pulmonary Arterial Hypertension (PAH) Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
- 1.3.2 Hospital
- 1.3.3 Clinic
- 1.4 Study Objectives
- 1.5 Years Considered
2 Global Growth Trends
- 2.1 Global Pulmonary Arterial Hypertension (PAH) Market Perspective (2017-2028)
- 2.2 Pulmonary Arterial Hypertension (PAH) Growth Trends by Region
- 2.2.1 Pulmonary Arterial Hypertension (PAH) Market Size by Region: 2017 VS 2021 VS 2028
- 2.2.2 Pulmonary Arterial Hypertension (PAH) Historic Market Size by Region (2017-2022)
- 2.2.3 Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Region (2023-2028)
- 2.3 Pulmonary Arterial Hypertension (PAH) Market Dynamics
- 2.3.1 Pulmonary Arterial Hypertension (PAH) Industry Trends
- 2.3.2 Pulmonary Arterial Hypertension (PAH) Market Drivers
- 2.3.3 Pulmonary Arterial Hypertension (PAH) Market Challenges
- 2.3.4 Pulmonary Arterial Hypertension (PAH) Market Restraints
3 Competition Landscape by Key Players
- 3.1 Global Top Pulmonary Arterial Hypertension (PAH) Players by Revenue
- 3.1.1 Global Top Pulmonary Arterial Hypertension (PAH) Players by Revenue (2017-2022)
- 3.1.2 Global Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Players (2017-2022)
- 3.2 Global Pulmonary Arterial Hypertension (PAH) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.3 Players Covered: Ranking by Pulmonary Arterial Hypertension (PAH) Revenue
- 3.4 Global Pulmonary Arterial Hypertension (PAH) Market Concentration Ratio
- 3.4.1 Global Pulmonary Arterial Hypertension (PAH) Market Concentration Ratio (CR5 and HHI)
- 3.4.2 Global Top 10 and Top 5 Companies by Pulmonary Arterial Hypertension (PAH) Revenue in 2021
- 3.5 Pulmonary Arterial Hypertension (PAH) Key Players Head office and Area Served
- 3.6 Key Players Pulmonary Arterial Hypertension (PAH) Product Solution and Service
- 3.7 Date of Enter into Pulmonary Arterial Hypertension (PAH) Market
- 3.8 Mergers & Acquisitions, Expansion Plans
4 Pulmonary Arterial Hypertension (PAH) Breakdown Data by Type
- 4.1 Global Pulmonary Arterial Hypertension (PAH) Historic Market Size by Type (2017-2022)
- 4.2 Global Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Type (2023-2028)
5 Pulmonary Arterial Hypertension (PAH) Breakdown Data by Application
- 5.1 Global Pulmonary Arterial Hypertension (PAH) Historic Market Size by Application (2017-2022)
- 5.2 Global Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Application (2023-2028)
6 North America
- 6.1 North America Pulmonary Arterial Hypertension (PAH) Market Size (2017-2028)
- 6.2 North America Pulmonary Arterial Hypertension (PAH) Market Size by Type
- 6.2.1 North America Pulmonary Arterial Hypertension (PAH) Market Size by Type (2017-2022)
- 6.2.2 North America Pulmonary Arterial Hypertension (PAH) Market Size by Type (2023-2028)
- 6.2.3 North America Pulmonary Arterial Hypertension (PAH) Market Share by Type (2017-2028)
- 6.3 North America Pulmonary Arterial Hypertension (PAH) Market Size by Application
- 6.3.1 North America Pulmonary Arterial Hypertension (PAH) Market Size by Application (2017-2022)
- 6.3.2 North America Pulmonary Arterial Hypertension (PAH) Market Size by Application (2023-2028)
- 6.3.3 North America Pulmonary Arterial Hypertension (PAH) Market Share by Application (2017-2028)
- 6.4 North America Pulmonary Arterial Hypertension (PAH) Market Size by Country
- 6.4.1 North America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2017-2022)
- 6.4.2 North America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2023-2028)
- 6.4.3 U.S.
- 6.4.4 Canada
7 Europe
- 7.1 Europe Pulmonary Arterial Hypertension (PAH) Market Size (2017-2028)
- 7.2 Europe Pulmonary Arterial Hypertension (PAH) Market Size by Type
- 7.2.1 Europe Pulmonary Arterial Hypertension (PAH) Market Size by Type (2017-2022)
- 7.2.2 Europe Pulmonary Arterial Hypertension (PAH) Market Size by Type (2023-2028)
- 7.2.3 Europe Pulmonary Arterial Hypertension (PAH) Market Share by Type (2017-2028)
- 7.3 Europe Pulmonary Arterial Hypertension (PAH) Market Size by Application
- 7.3.1 Europe Pulmonary Arterial Hypertension (PAH) Market Size by Application (2017-2022)
- 7.3.2 Europe Pulmonary Arterial Hypertension (PAH) Market Size by Application (2023-2028)
- 7.3.3 Europe Pulmonary Arterial Hypertension (PAH) Market Share by Application (2017-2028)
- 7.4 Europe Pulmonary Arterial Hypertension (PAH) Market Size by Country
- 7.4.1 Europe Pulmonary Arterial Hypertension (PAH) Market Size by Country (2017-2022)
- 7.4.2 Europe Pulmonary Arterial Hypertension (PAH) Market Size by Country (2023-2028)
- 7.4.3 Germany
- 7.4.4 France
- 7.4.5 U.K.
- 7.4.6 Italy
- 7.4.7 Russia
- 7.4.8 Nordic Countries
8 Asia-Pacific
- 8.1 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size (2017-2028)
- 8.2 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Type
- 8.2.1 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Type (2017-2022)
- 8.2.2 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Type (2023-2028)
- 8.2.3 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Share by Type (2017-2028)
- 8.3 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Application
- 8.3.1 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Application (2017-2022)
- 8.3.2 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Application (2023-2028)
- 8.3.3 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Share by Application (2017-2028)
- 8.4 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Region
- 8.4.1 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Region (2017-2022)
- 8.4.2 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Region (2023-2028)
- 8.4.3 China
- 8.4.4 Japan
- 8.4.5 South Korea
- 8.4.6 Southeast Asia
- 8.4.7 India
- 8.4.8 Australia
9 Latin America
- 9.1 Latin America Pulmonary Arterial Hypertension (PAH) Market Size (2017-2028)
- 9.2 Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Type
- 9.2.1 Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Type (2017-2022)
- 9.2.2 Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Type (2023-2028)
- 9.2.3 Latin America Pulmonary Arterial Hypertension (PAH) Market Share by Type (2017-2028)
- 9.3 Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Application
- 9.3.1 Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Application (2017-2022)
- 9.3.2 Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Application (2023-2028)
- 9.3.3 Latin America Pulmonary Arterial Hypertension (PAH) Market Share by Application (2017-2028)
- 9.4 Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Country
- 9.4.1 Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2017-2022)
- 9.4.2 Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2023-2028)
- 9.4.3 Mexico
- 9.4.4 Brazil
10 Middle East & Africa
- 10.1 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size (2017-2028)
- 10.2 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Type
- 10.2.1 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Type (2017-2022)
- 10.2.2 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Type (2023-2028)
- 10.2.3 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Share by Type (2017-2028)
- 10.3 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Application
- 10.3.1 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Application (2017-2022)
- 10.3.2 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Application (2023-2028)
- 10.3.3 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Share by Application (2017-2028)
- 10.4 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Country
- 10.4.1 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Country (2017-2022)
- 10.4.2 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Country (2023-2028)
- 10.4.3 Turkey
- 10.4.4 Saudi Arabia
- 10.4.5 UAE
11 Key Players Profiles
- 11.1 Actelion
- 11.1.1 Actelion Company Details
- 11.1.2 Actelion Business Overview
- 11.1.3 Actelion Pulmonary Arterial Hypertension (PAH) Introduction
- 11.1.4 Actelion Revenue in Pulmonary Arterial Hypertension (PAH) Business (2017-2022)
- 11.1.5 Actelion Recent Developments
- 11.2 Gilead Sciences
- 11.2.1 Gilead Sciences Company Details
- 11.2.2 Gilead Sciences Business Overview
- 11.2.3 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Introduction
- 11.2.4 Gilead Sciences Revenue in Pulmonary Arterial Hypertension (PAH) Business (2017-2022)
- 11.2.5 Gilead Sciences Recent Developments
- 11.3 United Therapeutics
- 11.3.1 United Therapeutics Company Details
- 11.3.2 United Therapeutics Business Overview
- 11.3.3 United Therapeutics Pulmonary Arterial Hypertension (PAH) Introduction
- 11.3.4 United Therapeutics Revenue in Pulmonary Arterial Hypertension (PAH) Business (2017-2022)
- 11.3.5 United Therapeutics Recent Developments
- 11.4 GlaxoSmithKline
- 11.4.1 GlaxoSmithKline Company Details
- 11.4.2 GlaxoSmithKline Business Overview
- 11.4.3 GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Introduction
- 11.4.4 GlaxoSmithKline Revenue in Pulmonary Arterial Hypertension (PAH) Business (2017-2022)
- 11.4.5 GlaxoSmithKline Recent Developments
- 11.5 Pfizer
- 11.5.1 Pfizer Company Details
- 11.5.2 Pfizer Business Overview
- 11.5.3 Pfizer Pulmonary Arterial Hypertension (PAH) Introduction
- 11.5.4 Pfizer Revenue in Pulmonary Arterial Hypertension (PAH) Business (2017-2022)
- 11.5.5 Pfizer Recent Developments
- 11.6 Bayer
- 11.6.1 Bayer Company Details
- 11.6.2 Bayer Business Overview
- 11.6.3 Bayer Pulmonary Arterial Hypertension (PAH) Introduction
- 11.6.4 Bayer Revenue in Pulmonary Arterial Hypertension (PAH) Business (2017-2022)
- 11.6.5 Bayer Recent Developments
- 11.7 Arena
- 11.7.1 Arena Company Details
- 11.7.2 Arena Business Overview
- 11.7.3 Arena Pulmonary Arterial Hypertension (PAH) Introduction
- 11.7.4 Arena Revenue in Pulmonary Arterial Hypertension (PAH) Business (2017-2022)
- 11.7.5 Arena Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
- 13.1 Research Methodology
- 13.1.1 Methodology/Research Approach
- 13.1.2 Data Source
- 13.2 Author Details
- 13.3 Disclaimer